Prothena Corporation plc

Prothena is a clinical-stage neuroscience company focused on the discovery and development of novel therapies with the potential to fundamentally change the course of devastating neurological disorders.We are advancing a pipeline of therapeutic candidates for a number of indications and novel targets including Parkinson’s disease and other related synucleinopathies (prasinezumab, PRX002/RG7935) and ATTR amyloidosis (PRX004), as well as tau, and TDP-43 where our scientific understanding of disease pathology can be leveraged.Prior to December 2012, Prothena’s business operated as part of Elan Corporation, plc. Prothena’s business consists of a substantial portion of Elan’s former drug discovery business platform. After the separation from Elan and the related distribution of our ordinary shares to Elan’s stockholders, our ordinary shares began trading on The Nasdaq Global Market under the symbol “PRTA” on December 21, 2012.For more information, please visit the Company's website at www.prothena.com and follow us @ProthenaCorp.